Company Filing History:
4 out of 263 
4 out of 987 
2 out of 167 Years Active: 2018-2023
Title: The Innovative Contributions of Anthony Barrett
Introduction
Anthony Barrett is a notable inventor based in London, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit cyclin-dependent kinases (CDKs). With a total of 4 patents to his name, Barrett's work has the potential to impact various therapeutic areas.
Latest Patents
One of Barrett's latest patents involves pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors. These compounds are designed to inhibit various CDKs, including CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, and CDK13. The patent outlines pharmaceutical compositions that utilize these compounds to treat disorders associated with CDK activity, such as cancer, viral infections, neurodegenerative disorders, ischaemia, renal diseases, and cardiovascular disorders. The treatment may also include simultaneous or sequential administration of additional active agents, enhancing its therapeutic efficacy.
Career Highlights
Throughout his career, Anthony Barrett has worked with esteemed organizations, including Cancer Research Technology Limited and Emory University. His experience in these institutions has allowed him to collaborate on groundbreaking research and development projects.
Collaborations
Barrett has collaborated with notable colleagues, including Alexander Bondke and Sebastian Kroll. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.
Conclusion
Anthony Barrett's innovative work in the field of CDK inhibitors showcases his commitment to advancing medical science. His contributions have the potential to lead to significant improvements in the treatment of various diseases.